{"filing":{"accession_number":"0001437749-26-021208","cik":"0001053691","ticker":"CRVO","company_name":"CervoMed Inc.","form":"8-K","filing_date":"2026-06-18","report_date":null,"primary_document":"crvo20260618_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1053691/000143774926021208/crvo20260618_8k.htm"},"events":[{"id":12495,"run_id":11071,"accession_number":"0001437749-26-021208","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"CervoMed entered into a Securities Purchase Agreement for a registered direct offering of 2,500,000 shares of common stock at $4.00 per share, raising $10 million in gross proceeds. The offering includes placement agent warrants equal to 6.0% of shares issued and represents a material dilutive equity issuance to existing shareholders.","company_name":"CervoMed Inc.","ticker":"CRVO","filing_date":"2026-06-18","form":"8-K","submitted_at":null,"items":[{"id":9361,"accession_number":"0001437749-26-021208","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"CervoMed entered into a Securities Purchase Agreement to issue 2,500,000 shares of common stock at $4.00 per share for $10 million gross proceeds in a registered direct offering. While technically registered under Form S-3, this is a direct offering to specific investors (not a public offering) and represents a dilutive equity issuance. The company also issued placement agent warrants equal to 6.0% of shares issued. This is material to investors as it dilutes existing shareholders and signals the company's capital needs.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T10:04:42.236281+00:00","company_name":"","ticker":null,"filing_date":""},{"id":9362,"accession_number":"0001437749-26-021208","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"CervoMed announced a registered direct offering of 2.5 million shares at $4.00 per share for $10 million in gross proceeds. Although technically registered under an effective Form S-3 shelf registration statement (File No. 333-282494), this is a direct offering to institutional investors at a fixed price, which is a form of dilutive equity issuance material to investors assessing capital structure and ownership dilution. The filing explicitly references Item 3.02 (Unregistered Sales of Equity Securities), though the offering is technically registered; the substance is a material equity raise that dilutes existing shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T10:04:42.236281+00:00","company_name":"","ticker":null,"filing_date":""},{"id":9363,"accession_number":"0001437749-26-021208","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"CervoMed announced a registered direct offering of 2.5 million shares of common stock at $4.00 per share for gross proceeds of $10 million. This is a registered equity issuance under an effective Form S-3 shelf registration statement, representing a dilutive capital raise. The filing explicitly discloses the offering structure, pricing, expected closing date, and use of proceeds for working capital and general corporate purposes, which is material to investors assessing the company's capital structure and financing activities.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T10:04:42.236281+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9361,"accession_number":"0001437749-26-021208","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"CervoMed entered into a Securities Purchase Agreement to issue 2,500,000 shares of common stock at $4.00 per share for $10 million gross proceeds in a registered direct offering. While technically registered under Form S-3, this is a direct offering to specific investors (not a public offering) and represents a dilutive equity issuance. The company also issued placement agent warrants equal to 6.0% of shares issued. This is material to investors as it dilutes existing shareholders and signals the company's capital needs.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T10:04:42.236281+00:00","company_name":"CervoMed Inc.","ticker":"CRVO","filing_date":"2026-06-18"},{"id":9362,"accession_number":"0001437749-26-021208","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"CervoMed announced a registered direct offering of 2.5 million shares at $4.00 per share for $10 million in gross proceeds. Although technically registered under an effective Form S-3 shelf registration statement (File No. 333-282494), this is a direct offering to institutional investors at a fixed price, which is a form of dilutive equity issuance material to investors assessing capital structure and ownership dilution. The filing explicitly references Item 3.02 (Unregistered Sales of Equity Securities), though the offering is technically registered; the substance is a material equity raise that dilutes existing shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T10:04:42.236281+00:00","company_name":"CervoMed Inc.","ticker":"CRVO","filing_date":"2026-06-18"},{"id":9363,"accession_number":"0001437749-26-021208","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"CervoMed announced a registered direct offering of 2.5 million shares of common stock at $4.00 per share for gross proceeds of $10 million. This is a registered equity issuance under an effective Form S-3 shelf registration statement, representing a dilutive capital raise. The filing explicitly discloses the offering structure, pricing, expected closing date, and use of proceeds for working capital and general corporate purposes, which is material to investors assessing the company's capital structure and financing activities.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T10:04:42.236281+00:00","company_name":"CervoMed Inc.","ticker":"CRVO","filing_date":"2026-06-18"}]}